

SARDA PROTEINS LTD.
Reg. Office: B-536-537, Matsya Industrial Area,
Alwar- 301030 (Rajasthan)
Corporate office: Inside Data Ingenious Global Limited,
Station Road, Durgapura, Jaipur-302018 (Rajasthan)
CIN: L15142RJ1991PLC006353
Phone: +91-7737822222
E Mail: sardaproteins@yahoo.com
Website: www.sardaproteins.com

Date: 13.11.2019

To,
BSE Limited,
25th Floor, P.J. Towers,
Dalal Street,
Mumbai-400 001

(BY BSE LISTING CENTRE)

Sub: Outcome of the Board Meeting held on Wednesday, 13th November, 2019 pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Ref.: Sarda Proteins Ltd., Scrip Code: 519242, Security ID: SRDAPRT.

Respected Sir/Ma'am,

The Board of Directors of the Company in their meeting held on Wednesday, the 13th day of November, 2019, which commenced at 04:00 P.M. and concluded at 06:50 P.M. at the corporate office of the company situated at Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan) *inter-alia*, transacted the following business:

1. Approved the Un-Audited Financial Results of the Company for the quarter and half year ended 30th September, 2019 alongwith the statement of assets and liabilities as on that date and Cash Flow Statements for the half year ended 30th September, 2019 pursuant to Regulation 33 of Listing Regulations (Enclosed herewith).

Further, the extract of the Un-Audited Financial results would also be published in the newspapers in compliance with Regulation 47 of Listing Regulations;

2. Took on record the Limited Review Report on Un-Audited Financial Results of the Company for the quarter and half year ended 30th September, 2019 (Enclosed herewith).

TRADING WINDOW:


Further in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company's code of conduct for Prohibition of Insider Trading the "Trading Window" for trading in the shares of the Company will open from 16th November, 2019 for the Directors and Key Managerial Personnel/ Designated Employees/ Connected Persons of the Company.

You are requested to kindly take the same on record.

Thanking you,
Yours faithfully,

FOR SARDA PROTEINS LTD.

FOR SARDA PROTEINS LTD.


AMIT KUMAR MODI
Company Secretary
**COMPANY SECRETARY &
COMPLIANCE OFFICER**
M.NO.: 29371


Encl: a/a

SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com
CIN: L15142RJ1991PLC006353

STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2019

S. No.	Particulars	Rs.in Lakhs					
		Quarter ended			Half Year ended		Year ended
		30.09.2019 Un-Audited	30.06.2019 Un-Audited	30.09.2018 Un-Audited	30.09.2019 Un-Audited	30.09.2018 Un-Audited	31.03.2019 (Audited)
I.	Revenue from Operations	171.81	37.75	203.30	209.56	299.20	714.51
II.	Other Income	4.05	0.01	-	4.06	2.93	10.15
III.	Total Income (I+II)	175.86	37.76	203.30	213.62	302.13	724.66
IV.	Expenses:						
	Cost of Material Consumed	-	-	-	-	-	-
	Purchase of Stock -in- Trade	170.75	37.25	202.60	208.00	254.07	659.65
	Changes in inventories of:						
	Finished Goods	-	-	-	-	-	-
	Work in Progress	-	-	-	-	-	-
	Stock in Trade	-	-	-	-	42.82	42.82
	Employee Benefit Expenses	3.01	3.37	5.38	6.38	11.64	18.35
	Finance Cost	0.02	0.01	(0.01)	0.03	-	0.20
	Depreciation and Amortisation Expenses	0.06	0.20	0.22	0.26	0.44	0.90
	Other expenses	0.85	4.22	2.50	5.07	8.19	11.48
	Total Expenses (IV)	174.69	45.05	210.69	219.74	317.16	733.40
V.	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	1.17	(7.29)	(7.39)	(6.12)	(15.03)	(8.74)
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit/(Loss) before Tax (V-VI)	1.17	(7.29)	(7.39)	(6.12)	(15.03)	(8.74)
VIII.	Tax Expense:						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	(3.00)	-	(3.00)	3.61
IX.	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	1.17	(7.29)	(4.39)	(6.12)	(12.03)	(12.35)
X.	Profit/(Loss) from Discontinued Operations	-	-	-	-	-	-
XI.	Tax Expenses of Discontinued Operations	-	-	-	-	-	-
XII.	Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-	-	-
XIII.	Profit/(Loss) for the Period (IX+XII)	1.17	(7.29)	(4.39)	(6.12)	(12.03)	(12.35)
XIV.	Other Comprehensive Income						
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other Comprehensive Income for the period)	1.17	(7.29)	(4.39)	(6.12)	(12.03)	(12.35)
XVI.	Earnings per Equity Share						
	(1) Basic	0.07	(0.42)	(0.25)	(0.35)	(0.70)	(0.72)
	(2) Diluted	0.07	(0.42)	(0.25)	(0.35)	(0.70)	(0.72)
XVII.	Paid Up Equity Share Capital, Equity Shares Of Face Value Rs. 10 each	172.59	172.59	172.59	172.59	172.59	172.59



For Sarda Proteins Limited

Director

SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com
CIN: L15142RJ1991PLC006353

STATEMENT OF ASSETS AND LIABILITIES FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2019

Particulars		Rs in Lakhs		
		Six Months ended		Year ended
		30.09.2019 (Un-Audited)	30.09.2018 (Un-Audited)	31.03.2019 (Audited)
A. ASSETS				
1. Non-Current Assets				
a) Property, Plant and Equipment		0.65	2.22	1.77
b) Capital work in progress		-	-	-
c) Investment Property		-	-	-
d) Goodwill		-	-	-
e) Other Intangible Assets		-	-	-
f) Intangible Assets under Development		-	-	-
g) Biological Assets other than bearer plants		-	-	-
h) Financial Assets		-	-	-
i) Investments		0.13	0.13	0.13
ii) Trade Receivables		-	-	-
iii) Loans		-	0.01	0.01
i) Deferred Tax Assets (net)		40.92	47.53	40.92
j) Other non-current Assets		0.21	0.17	0.22
2. Current Assets				
a) Inventories		-	-	-
b) Financial Assets		-	-	-
i) Investments		-	-	-
ii) Trade Receivables		243.92	72.87	71.99
iii) Cash and Cash Equivalents		0.25	0.42	6.96
iv) Bank Balances and other than (iii) above		3.65	4.40	-
v) Loans		95.38	88.00	97.49
v) Others		0.01	0.92	-
c) Current Tax Assets (net)		-	-	-
d) Other Current Assets		-	-	-
Total Assets		385.12	216.67	219.49
B. EQUITY AND LIABILITIES				
1. Equity				
a) Equity Share Capital		250.45	250.45	250.45
b) Other Equity		(49.93)	(43.50)	(43.81)
2. Liabilities				
Non current Liabilities				
a) Financial Liabilities				
i) Borrowings		-	-	-
ii) Trade Payables		-	-	-
A) Total Outstanding dues to MSEs		-	-	-
B) Total Outstanding dues to Creditors other than MSEs		-	-	-
iii) Other Financial Liabilities		-	-	-
b) Provisions		3.67	9.34	9.95
c) Deferred Tax Liabilities (net)		-	-	-
d) Other Non Current Liabilities		-	-	-
Current Liabilities				
a) Financial Liabilities				
i) Borrowings		-	-	0.73
ii) Trade Payables		-	-	-
A) Total Outstanding dues to MSEs		-	-	-
B) Total Outstanding dues to Creditors other than MSEs		180.06	0.38	-
iii) Other Financial Liabilities		-	-	-
b) Other Current Liabilities		0.87	-	2.17
c) Provisions		-	-	-
d) Current Tax Liabilities (net)		-	-	-
Total Equity and Liabilities		385.12	216.67	219.49



For Sarda Proteins Limited


Director

SARDA PROTEINS LTD


Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com
CIN: L15142RJ1991PLC006353

FINAL CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER 2019

Particulars		Six Months ended		Rs in Lakhs
		30.09.2019	30.09.2018	Year ended
		(Un-Audited)	(Un-Audited)	31.03.2019 (Audited)
CASH FLOW FROM OPERATING ACTIVITIES				
	Net Profit before Tax and Extraordinary Items	(6.12)	(12.03)	(8.74)
A.	ADJUSTMENT FOR			
	Depreciation	0.26	0.44	0.90
	Interest Received	(0.10)	(2.93)	(7.22)
	Profit on Sale of Investment	-	-	(2.93)
	Dividend	-	-	-
	(Profit) /Loss on sale of Fixed Assets	0.03	-	-
	Interest Paid	0.04	-	0.20
	Operating Profit/(Loss) before Working Capital Charges	(5.90)	(14.52)	(17.79)
	ADJUSTMENT FOR:			
	Trade and other Receivables	(169.77)	3.96	(82.48)
	Inventories	-	42.99	42.99
	Trade & other Payables	171.75	(3.75)	(1.36)
	Cash Generated from Operations	1.98	43.20	(58.64)
	Direct Taxes Paid	-	(3.00)	-
	Net Cash from Operating Activities	(3.92)	25.68	(58.64)
B.	CASH FLOW FROM INVESTING ACTIVITIES			
	Capital Expenditure	-	-	-
	Sale of Fixed Assets	0.83	-	-
	Profit/ (Loss) on sale of Fixed Assets	(0.03)	-	-
	Profit on sale of Investment	-	-	2.93
	Sale of Investment	-	1.18	1.18
	Interest Received	0.10	2.93	7.22
	Dividend Received	-	-	-
	Net Cash Received from Investing Activities	0.90	4.11	11.33
C.	CASH FLOW FROM FINANCING ACTIVITIES			
	Proceeds from Long Term Borrowings	-	-	-
	Proceeds from Short Term Borrowings	-	(78.71)	0.73
	Interest Paid	(0.04)	-	(0.20)
	Net Cash Inflow/ (Outflow) from Financing Activities	(0.04)	(78.71)	0.53
	Net Cash Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(3.06)	(48.92)	(46.77)
	Cash & Cash Equivalents (Opening)	6.96	53.74	53.74
	Cash & Cash Equivalents (Closing)	3.90	4.82	6.96

Notes:

1. The above results were approved by Audit Committee and Board of Directors in their meeting held on 13th November 2019.
2. Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
3. Segment Results as per AS is not applicable as dealing in only one segment i.e. " Agro Products".
4. No Investor Complaints were received during the quarter ended 30-Sep-2019 nor any pending as on 01-Oct-2019.




Place: Jaipur
Date : 13-Nov-2019

on behalf of the Board
Sarda Proteins Ltd
For Sarda Proteins Limited

Deepak Data (DIN: 01672415)
Managing Director

Director



Khetawat Agarwal & Co.
Chartered Accountants

INDEPENDENT AUDITORS REVIEW REPORT

To,
The Board Of Director
Sarda Proteins Limited

We have reviewed the accompanying statement of standalone unaudited financial results of **Sarda proteins Limited** for the quarter and three months ended September 30, 2019, being submitted by the Company pursuant to the requirements of Regulation 33 of Securities and Exchange Board Of India (Listing obligations and Disclosures Requirements) Regulations, 2015 as modified by circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down by the Indian Accounting Standards 34 "Interim Financial Reporting" ("IND-AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant Rules issued thereunder and other Accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Engagements to "Review of Interim Financial information reviewed by Independent Auditor of the Entity"* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone unaudited financial results read with notes thereon prepared in accordance with aforesaid Indian accounting standards and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.


Place: Alwar
Date: November 13, 2019

UDIN: 19072854AAAACX6697

For Khetawat Agarwal & Co.
Chartered Accountants

FRN: 003960C




M.L. Agarwal
Partner
(M. No: 072854)